SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

A burst of launch activity, including three orbital launches in roughly 13 hours and Starships deployment of Starlink V3 satellites, is driving attention and optimism about SpaceXs execution. Traders are also debating whether the rally can continue or whether valuation concerns, share unlocks and resistance could bring a pullback.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. It operates through the Hard Disk Drives (HDD) segment. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Toshibas reported plan to double HDD capacity for AI data centers fueled a sharp WDC selloff on fears of added competition and weaker pricing power. Traders debated whether the reaction was excessive given the delayed expansion and strong AI-storage demand, or whether added supply could eventually pressure margins and market share.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nikes quarterly report paired an earnings beat with weaker sales and a cautious full-year outlook, while China weakness and a slower turnaround drew analyst target cuts and selling pressure. Traders are divided between calling the drop an oversold buying opportunity with squeeze potential and seeing further downside risk as the business recovery lags.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

CBRS discussion centers on uncertainty over whether Cerebras can win AI-inference business alongside Nvidia, including reports that an OpenAI model tier is using Nvidia GPUs, and the overhang from insider share unlocks and sales. Bears cite those risks and valuation, while bulls point to Cerebras contracts, partnerships, and demand for its chips; the catalyst debate remains unresolved.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

New RAMP 201 analyses of Verastems avutometinibdefactinib combination in recurrent low-grade serous ovarian cancer are drawing attention, especially findings in KRAS wild-type patients and comparisons with conventional care that traders say could broaden the treatment opportunity. The discussion is optimistic about the potential but frustrated by the muted share-price response, while many are also watching for the upcoming VS-7375 clinical update.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

Discussion centers on CRMDs weak share performance despite strong results and a DaVita DefenCath agreement, with traders debating whether post-TDAPA reimbursement pressure can be offset by greater adoption, Medicare Advantage coverage, or policy changes. Bulls also point to cash generation and REZZAYOs development potential, while skeptics cite limited near-term visibility and reimbursement uncertainty.

Redwire Corp. engages in the development and provision of space and defense technologies and mission-critical solutions for government, commercial, and civil customers. Its offerings include spacecraft platforms, space infrastructure, avionics, sensors and payloads, power generation systems, radio frequency systems, microgravity research and manufacturing technologies, autonomous systems, optical sensors, and digital engineering solutions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwires selection for a Space Force contract vehicle is a major focus, with traders viewing it as validation of the companys defense-space pipeline while noting that the award guarantees no revenue. The community is split between optimism about future contracts and frustration with weak, volatile share-price action and the need for concrete orders.

Vistra Corp. is a holding company, which engages in the provision of electricity and power generation. It operates through the following segments: Retail, Texas, East, West, and Asset Closure. The Retail segment includes sale of electricity and natural gas to residential, commercial, and industrial customers. The Texas and East segments are involved in electricity generation, wholesale energy sales and purchases, commodity risk management activities, fuel production and fuel logistics management. The West segment represents the company's electricity generation operations in CAISO. The Asset Closure segment refers to the decommissioning and reclamation of retired plants and mines. The company was founded in 1882 and is headquartered in Irving, TX.

Vistra Corp

Reports that the U.S. government may offer Vistra a $4 billion loan to expand nuclear output are drawing attention, but traders are frustrated that the shares faded rather than rallying on the news. The reaction contrasts with longer-term optimism about AI-driven power demand and complaints about persistent volatility and selling pressure.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians record Q3 deliveries topped analyst expectations as the R2 ramp gained momentum, but the company reaffirmed rather than raised its annual guidance. Traders are split between viewing the volume growth as progress and seeing the share-price decline as a sell-the-news reaction, with profitability and the pace of the production ramp still concerns.

Armada Acquisition Corp. II is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combinations with one or more businesses. The company was founded on October 3, 2024 and is headquartered in Miami, FL.

Armada Acquisition Corp. II - Ordinary Shares- Class A

Evernorth Holdings Inc.

Evernorths shareholder-approved combination with Armada II, which is expected to create a publicly traded XRP treasury holding roughly 473 million XRP, is driving XRPNs sharp rally. Traders are debating whether the move reflects XRP-treasury interest and a potentially tight public float or speculative SPAC hype, with redemptions and warrants in focus and skeptics warning of volatility and valuation risk.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioMarin Announces Five-Year Phase 3 Data for POMBILITI (cipaglucosidase alfa-atga) + OPFOLDA (miglustat) at World Muscle Society Annual Congress

BioMarin Announces Five-Year Phase 3 Data for POMBILITI (cipaglucosidase alfa-atga) + OPFOLDA (miglustat) at World Muscle Society Annual Congress BioMarin Announces Five-Year Phase 3 Data for POMBILITI (cipaglucosidase alfa-atga) + OPFOLDA (miglustat) at World Muscle Society Annual CongressPR...

FDA Grants Priority Review to AZN's Filing for Rare Bone Disease Drug

AstraZeneca wins FDA priority review for efzimfotase alfa, potentially expanding its HPP treatment opportunity with less frequent dosing.

BioMarin Stops Voxzogo Development for Noonan Syndrome

BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.

BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors

BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of DirectorsPR NewswireSAN RAFAEL, Calif., Sept...

BioMarin Reports Positive Phase 3 Results For VOXZOGO

(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN) on Wednesday announced positive Phase 3 results for VOXZOGO (vosoritide) in children with hypochondroplasia, with the study meeting its primary endpoint and all secondary efficacy endpoints...

BioMarin Announces Positive Results of Phase 3 VOXZOGO (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence

BioMarin Announces Positive Results of Phase 3 VOXZOGO (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence BioMarin Announces Positive Results of Phase 3 VOXZOGO (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence PR Newswire SAN RAFAEL, Calif., Sept. 9, 2026 Detailed...

EVP At BioMarin Pharmaceutical Sells $1.16M Of Stock

Eric George Davis, EVP at BioMarin Pharmaceutical (NASDAQ:BMRN), reported an insider sell on September 3, according to a new SEC filing.
What Happened: Davis opted to sell 17,557 shares of BioMarin Pharmaceutical,read more...

RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout 

Equity

Wall Street removed the Angelman program from valuation models, slashing price targets by as much as 76% and issuing multiple downgrades.

How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset

BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.

BioMarin to Participate in Upcoming Investor Conferences

BioMarin to Participate in Upcoming Investor Conferences BioMarin to Participate in Upcoming Investor Conferences PR Newswire SAN RAFAEL, Calif., Sept. 2, 2026 Wells Fargo 21st Annual Healthcare Conference, September 9 at 3:00 pm ESTCantor Global Healthcare Conference 2026, September 10 at 10:20 am...

BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

Biomarin Pharmaceutical Inc. - Registered Shares

Neutral Sentiment

Up more than 5%

Flat to up 5%

Flat to down 5%

Down more than 5%

What&#39;s your expected total return for the S&amp;P 500 ($SPY) in Q4? 

Drop your reasoning in the comments.

Stocktwits

What's your expected total return for the S&P 500 (

) in Q4? 

Drop your reasoning in the comments.

Current Price	$57.55
Prev Close	$58.44
Open	$58.62
Dividend Yield	0.00%
50-Day Moving Average	$64.02
Beta	0.65
Avg. Volume	2M
PE Ratio	157.56

52-Week High	$70.98
52-Week Low	$49.26
Market Capitalization	$11.31B
EPS (Annual)	$1.80
Price to Book	1.79
Revenue Per Employee	$1.01M

Feed

News

Sentiment

Earnings

Fundamentals

Info

BMRN Fundamentals